Nefopam Hydrochloride Focus Pharmaceuticals Ltd (Nefopam Hydrochloride)

• Nefopam Hydrochloride is a central analgesic used to manage moderate acute pain conditions.
• Acute postoperative pain: provides effective analgesia during the recovery period after surgery.
• Musculoskeletal pain: reduces pain associated with muscle strains, sprains and joint injuries.
• Other moderate acute pain: alleviates pain from dental procedures, trauma or other short‑term painful events.

• Nefopam Hydrochloride acts centrally by inhibiting the reuptake of norepinephrine, serotonin and dopamine, which enhances descending inhibitory pain pathways. This multimodal neurotransmitter modulation reduces neuronal excitability in the spinal cord and brain, leading to decreased perception of pain without engaging opioid receptors.

Nefopam Hydrochloride may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Nausea or vomiting
• Dry mouth
• Sweating or increased perspiration
• Dizziness or light‑headedness
• Constipation
• Blurred vision

Serious or Rare Side Effects

• Seizures, particularly in patients with a seizure history
• Severe hypotension or sudden drop in blood pressure
• Allergic reactions such as rash, angioedema or anaphylaxis
• Tachycardia or arrhythmias
• Hepatic dysfunction in rare cases

• Before prescribing Nefopam Hydrochloride, clinicians should consider several safety measures.
• Assess renal and hepatic function: adjust use if organ impairment is present.
• Monitor cardiovascular status: watch for hypotension or tachycardia.
• Use caution in patients with glaucoma: anticholinergic effects may worsen intra‑ocular pressure.
• Avoid abrupt discontinuation: taper if long‑term therapy is required.
• Evaluate for drug interactions: review concomitant serotonergic or MAO‑inhibiting agents.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nefopam Hydrochloride can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

• MAO inhibitors: risk of serotonin syndrome.
• Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): increased serotonin toxicity.
• Strong anticholinergic agents: additive anticholinergic burden.

Moderate Interactions (Monitor Closely)

• Antihypertensive drugs: possible additive hypotensive effect.
• Anticonvulsants: may lower seizure threshold.
• CYP450 substrates (e.g., warfarin, theophylline): potential alteration of plasma concentrations.